NCT02125175View on ClinicalTrials.gov

BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2019

Conditions
Prostate Cancer
Interventions
RADIATION

Hypofractionated IMRT boost Radiotherapy

Trial Locations (1)

CH63 4JY

The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington

All Listed Sponsors
lead

The Clatterbridge Cancer Centre NHS Foundation Trust

OTHER

NCT02125175 - BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer | Biotech Hunter | Biotech Hunter